N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Sponsor: Janssen Research & Development, LLC • ClinicalTrials.gov ID: NCT07149857

Registry updated: 2026-09-25
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.

Interventions

  • Cilta-cel (Drug)
    Cilta-cel will be administered as intravenous infusion.
  • Cyclophosphamide (Drug)
    Cyclophosphamide will be administered as intravenous infusion.
  • Induction therapy (Drug)
    Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd), will will be administered.
  • Fludarabine (Drug)
    Fludarabine will be administered as intravenous infusion.

Eligibility criteria

Inclusion Criteria * Documented diagnosis of newly diagnosed multiple myeloma (NDMM) according to the most recent international myeloma working group (IMWG) diagnostic criteria and measurable disease at diagnosis (prior to start of any anti-myeloma therapy): Serum monoclonal paraprotein (M-protein) level greater than equal to (\>=)1.0 grams per deciliter (g/dL) or urine M-protein level \>= 200 milligrams (mg)/24 hours; or light chain multiple myeloma in whom the only measurable disease is by serum free light chain (FLC) levels in the serum: involved serum free light chain \>= 10 mg/dL and abnormal serum free light chain ratio * Not considered a candidate for high-dose chemotherapy with stem cell transplantation due to: (a) Advanced age; or (b) Presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with stem cell transplantation; or (c) Participant refusal of high-dose chemotherapy with stem cell transplantation as initial treatment * Participant must have received at least 3 cycles and no more than 5 cycles of induction therapy. Initially, only participants receiving triplet induction therapy with DRd or VRd will be enrolled. Only after sponsor notification, participants receiving quadruplet DVRd induction therapy may be enrolled (screening can commence as early as during Cycle 3 of induction). Participants must have achieved \>= partial response (PR) on the most recent disease assessment to be enrolled * Eastern cooperative oncology group (ECOG) Performance Status score of 0 or 1 * Must be willing and able to adhere to the lifestyle restrictions specified in the protocol Exclusion Criteria * Frailty index of \>= 2 according to Myeloma Geriatric Assessment score * Known allergies, hypersensitivity, or intolerance to study intervention or its active agents * Grade 2 or higher ongoing non-hematologic toxicity due to induction therapy, with the exception of grade 2 peripheral neuropathy due to bortezomib * Participants who require continuous supplemental oxygen

Conditions

Multiple Myeloma

Locations

  • University of California San Francisco — San Francisco, California, United States
  • Moffitt Cancer Center — Tampa, Florida, United States
  • University of Iowa Hospital and Clinics — Iowa City, Iowa, United States
  • Memorial Sloan Kettering Cancer Center — New York, New York, United States
  • Atrium Health — Charlotte, North Carolina, United States
  • Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
  • Cleveland Clinic — Cleveland, Ohio, United States
  • Royal Prince Alfred Hospital — Camperdown, Australia
  • Monash Medical Centre — Clayton, Australia
  • Austin Hospital — Heidelberg, Australia
  • Fiona Stanley Hospital — Murdoch, Australia
  • Princess Alexandra Hospital — Woolloongabba, Australia
  • Hosp. Univ. Germans Trias I Pujol — Badalona, Spain
  • Hosp Univ Vall D Hebron — Barcelona, Spain
  • Hosp. Clinic de Barcelona — Barcelona, Spain
  • Hosp. Univ. 12 de Octubre — Madrid, Spain
  • Clinica Univ. de Navarra — Pamplona, Spain
  • Hosp Clinico Univ de Salamanca — Salamanca, Spain
  • Hosp. Univ. Marques de Valdecilla — Santander, Spain
  • Hosp. Virgen Del Rocio — Seville, Spain
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record